Undisclosed CDH17/CEACAM5 BsADC / Haisco - LARVOL DELTA

Preclinical development of a potential first-in-class CDH17/CEACAM5 targeted bispecific antibody drug conjugate (ADC) (AACR 2026) - "In summary, we have generated a promising CDH17/CEACAM5 bispecific ADC that delivers potent antitumor activity both in vitro and in vivo. The observed efficacy advantage over monovalent ADCs supports continued preclinical development and positions this bispecific ADC as a compelling therapeutic candidate for CRC patients."

ADC • Bispecific • Late-breaking abstract • Preclinical • Colorectal Cancer • Oncology • Solid Tumor • CDH17 • CEACAM5